Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial

MT Newswires Live12-22 08:48

Immutep (ASX:IMM) said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.

IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with "significant," long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.

The firm's shares fell past 1% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593711881?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 08:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593711881","market":"hk","top_or_hot":-1,"title":"Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial","media":"MT Newswires Live","content":"<html><body><p> Immutep (ASX:IMM) said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.</p><p>IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with \"significant,\" long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.</p><p>The firm's shares fell past 1% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-22 08:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Immutep (ASX:IMM) said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.</p><p>IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with \"significant,\" long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.</p><p>The firm's shares fell past 1% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMM.AU","symbol_name":"IMMUTEP LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593711881","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593711881","pubTimestamp":1766364498,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with \"significant,\" long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.The firm's shares fell past 1% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMM.AU":"IMMUTEP LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Immutep在1期自身免疫性疾病试验的单剂量递增部分中完成了两个剂量水平","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Immutep (ASX:IMM) said the single-ascending dose portion of its first-in-human phase one study evaluating its IMP761 treatment candidate, an antibody for autoimmune diseases, completed the 2.5-milligram-per-kilogram and 7-milligram-per-kilogram dosing levels in healthy participants, according to a Monday Australian bourse filing.IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity, per the filing. Evidence of dose-dependent immunosuppressive effects was observed with \"significant,\" long-lasting inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at days two, nine, and 23.The firm's shares fell past 1% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593711881","isCrawlerRequest":true}